A glucan from Ganoderma lucidum: Structural characterization and the anti-inflammatory effect on Parkinson's disease via regulating dysfunctions of intestinal microecology and inhibiting TLR4/MyD88/NF-κB signaling pathway

Feb 6, 2025Journal of ethnopharmacology

A sugar from Ganoderma lucidum reduces inflammation in Parkinson's disease by improving gut balance and blocking a key immune signaling pathway

AI simplified

Longevity & Aging on OpenScience ↗PubMed ↗DOI ↗

Abstract

A purified glucan, GLPZ-2, exhibits significant anti-inflammatory effects on Parkinson's disease.

GLPZ-2 has a triple helical structure primarily composed of various sugar linkages.
In a mouse model of Parkinson's disease, GLPZ-2 improved motor symptoms and reduced pathological damage.
Treatment with GLPZ-2 decreased the brain protein levels of α-Syn, IL-6, IL-1β, and TNF-α.
GLPZ-2 regulated gut microbiota and fecal metabolites, restoring them to normal levels.
GLPZ-2 increased the content of short-chain fatty acids (SCFAs) in the intestine.
The compound inhibited the TLR4/MyD88/NF-κB signaling pathway in intestinal cells.

AI simplified

ETHNOPHARMACOLOGICAL RELEVANCE: Ganoderma lucidum (Curtis) P. Karst (G. lucidum) is a traditional Chinese medicinal fungus, used to exert a beneficial effect on central nervous system, such as Parkinson's disease (PD). Polysaccharide is its main active ingredient, but the structural characterization and the mechanisms of the beneficial effect on PD remain to be elucidated.

AIM OF THE STUDY: To obtain a purified G. lucidum polysaccharide and elucidate its structure, investigate the anti-inflammatory effect on PD and explore its potential mechanisms.

MATERIALS AND METHODS: The structure of polysaccharide was analyzed through methylation analysis and NMR analysis. The anti-inflammatory effect on PD were explored in a MPTP-induced mouse model. A comprehensive microbiota-gut-metabolomics analysis was executed and subsequently deliberated, focusing on the regulation of dysfunctions of intestinal microecology. The potential mechanisms were investigated using a LPS-induced Caco-2 cell model.

RESULTS: A purified glucan, GLPZ-2 was obtained. GLPZ-2 was with triple helical structure and its backbone was found to be primarily composed of 1,6-α-D-Glcp, 1,4-α-D-Glcp, 1,4,6-α-D-Glcp and 1,3,6-β-D-Glcp, with branches at the C-3 and C-4 position by t-α-D-Glcp. PD mice experiments showed that GLPZ-2 could improve motor symptoms, reduce pathological damage and decrease brain protein expression of α-Syn, IL-6, IL-1β and TNF-α. GLPZ-2 also could regulate the gut microbiota and fecal metabolites to restore to normal trend, increase SCFAs content and inhibit TLR4/MyD88/NF-κB pathway in intestine.

CONCLUSIONS: GLPZ-2 exhibits an anti-inflammatory effect on PD, which provide a foundational basis for the application of GLPZ-2 as an effective drug to prevent and delay PD.

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

A glucan from Ganoderma lucidum: Structural characterization and the anti-inflammatory effect on Parkinson's disease via regulating dysfunctions of intestinal microecology and inhibiting TLR4/MyD88/NF-κB signaling pathway

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the longevity & aging brief